Neeraj Narula
Population Health Research Institute
Internal medicineSurgeryOdds ratioRetrospective cohort studyIntensive care medicineProspective cohort studyAdverse effectVedolizumabInfliximabInflammatory bowel diseaseColonoscopyUstekinumabDiseaseCrohn's diseaseAdalimumabUlcerative colitisIn patientConfidence intervalPost-hoc analysisMedicineGastroenterologyMeta-analysis
140Publications
23H-index
1,880Citations
Publications 140
Newest
#1Neeraj Narula (McMaster University)H-Index: 23
#2Emily C L Wong (McMaster University)H-Index: 2
Last. Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 29
view all 0 authors...
Abstract null null Background & Aims null The prognostic value of histologic scores, grades, and individual histologic sub-components, alone or in combination with endoscopy, for predicting endoscopic improvement (EI) and histo-endoscopic mucosal improvement (HEMI) during maintenance therapy in ulcerative colitis (UC) remains uncertain. null null null Methods null Post-hoc analysis of participants from the VARSITY trial (n=734 with histology). Receiver operating characteristic and multi-variate ...
Source
#1Conor Bell (McMaster University)H-Index: 1
#2Parul Tandon (U of T: University of Toronto)H-Index: 12
Last. Neeraj Narula (McMaster University)H-Index: 23
view all 0 authors...
BACKGROUND AND AIM Vedolizumab is a novel monoclonal antibody used in patients with inflammatory bowel disease, often affecting women of child-bearing age. We aimed to compare maternal and fetal adverse outcomes in pregnancies of women with inflammatory bowel disease exposed to vedolizumab versus those on other treatment. METHODS We performed a systematic literature search through December 2020 looking for studies including outcomes from pregnancies of female inflammatory bowel disease patients ...
Source
#1Neeraj Narula (Population Health Research Institute)H-Index: 23
#2Emily C L Wong (McMaster University)H-Index: 2
Last. Salim Yusuf (Population Health Research Institute)H-Index: 247
view all 0 authors...
Source
#1Neeraj Narula (McMaster University)H-Index: 23
#2Achuthan Aruljothy (McMaster University)H-Index: 3
Last. Walter Reinisch (Medical University of Vienna)H-Index: 100
view all 7 authors...
This post hoc analysis of the UNITI studies found ustekinumab (UST) did not significantly improve overall extraintestinal manifestations (EIMs) of Crohn's disease compared to placebo-treated patients at weeks 6 and 52. BACKGROUND AND AIMS The UNITI trials demonstrated that UST was effective in inducing and maintaining clinical remission in Crohn's disease (CD). However, limited data exists regarding its effectiveness for treatment of EIMs. This post hoc analysis evaluated the efficacy of UST in ...
2 CitationsSource
#1Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 29
#2Emily C L Wong (McMaster University)H-Index: 2
Last. Neeraj Narula (McMaster University)H-Index: 23
view all 0 authors...
Biologic treatment options for Crohn's disease (CD) are increasing and providers will need enhanced support in integrating these therapies into routine practice. Using phase 3 clinical trial programs in CD, we have previously built and validated clinical decision support tools for achieving clinical remission (CREM) with vedolizumab and ustekinumab in CD.1-4 We now aim to develop a clinical decision support tool for infliximab in CD.
Source
#1Wong Ecl (McMaster University)
#1Emily C L Wong (McMaster University)H-Index: 2
Last. Neeraj NarulaH-Index: 23
view all 7 authors...
Source
Source
Source
#1Neeraj Narula (McMaster University)H-Index: 23
#2Emily Cl Wong (McMaster University)
Last. Mark S. Silverberg (Mount Sinai Hospital)H-Index: 76
view all 10 authors...
BACKGROUND AND AIMS Crohn's disease (CD) patients who previously failed anti-TNF therapy are at higher risk of treatment failure with subsequent biologics. This study aims to determine the effectiveness and safety of higher maintenance dose regimens of adalimumab compared to standard doses in CD patients who failed anti-TNF. METHODS In this retrospective observational study, CD patients who failed anti-TNF and received adalimumab were categorized according to their post-induction maintenance reg...
Source
#1Emily C L Wong (McMaster University)H-Index: 2
#2John Marshall (McMaster University)H-Index: 89
Last. Neeraj Narula (McMaster University)H-Index: 23
view all 4 authors...
BACKGROUND This post hoc analysis aimed to evaluate the impact of BMI on the efficacy of ustekinumab in the IM-UNITI study. METHODS The relationship between body mass index (BMI) and efficacy of ustekinumab was evaluated using data from a 44-week maintenance study of ustekinumab in Crohn's disease (IM-UNITI, NCT01369355, YODA #2019-4105). The primary endpoints of interest were clinical remission (CR), defined as Crohn's disease activity index <150 and corticosteroid-free CR at week 44. Patients ...
Source